Inspire Medical Systems, Inc. (NYSE:INSP) is Bullseye Asset Management LLC’s 9th Largest Position

Bullseye Asset Management LLC boosted its position in Inspire Medical Systems, Inc. (NYSE:INSPFree Report) by 119.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 27,199 shares of the company’s stock after buying an additional 14,812 shares during the period. Inspire Medical Systems makes up about 2.6% of Bullseye Asset Management LLC’s holdings, making the stock its 9th biggest position. Bullseye Asset Management LLC owned approximately 0.09% of Inspire Medical Systems worth $5,534,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of INSP. Amalgamated Bank boosted its holdings in Inspire Medical Systems by 12.5% in the 3rd quarter. Amalgamated Bank now owns 7,023 shares of the company’s stock valued at $1,394,000 after purchasing an additional 779 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Inspire Medical Systems by 3.2% in the third quarter. Charles Schwab Investment Management Inc. now owns 256,222 shares of the company’s stock valued at $50,845,000 after buying an additional 7,838 shares in the last quarter. Van ECK Associates Corp grew its holdings in Inspire Medical Systems by 26.4% during the third quarter. Van ECK Associates Corp now owns 853 shares of the company’s stock worth $169,000 after acquiring an additional 178 shares during the period. State Board of Administration of Florida Retirement System raised its position in Inspire Medical Systems by 2.3% in the third quarter. State Board of Administration of Florida Retirement System now owns 32,714 shares of the company’s stock worth $6,492,000 after acquiring an additional 730 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its holdings in Inspire Medical Systems by 125.1% in the third quarter. DekaBank Deutsche Girozentrale now owns 29,820 shares of the company’s stock valued at $5,903,000 after acquiring an additional 16,570 shares during the period. 94.91% of the stock is owned by institutional investors and hedge funds.

Inspire Medical Systems Stock Down 0.3 %

NYSE INSP traded down $0.56 on Friday, reaching $166.72. The company had a trading volume of 300,903 shares, compared to its average volume of 570,517. Inspire Medical Systems, Inc. has a 1 year low of $123.27 and a 1 year high of $330.00. The firm has a 50-day moving average of $194.73 and a 200-day moving average of $192.42.

Inspire Medical Systems (NYSE:INSPGet Free Report) last issued its quarterly earnings data on Tuesday, May 7th. The company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.29. The firm had revenue of $164.01 million for the quarter, compared to analyst estimates of $161.41 million. Inspire Medical Systems had a negative net margin of 2.38% and a negative return on equity of 2.82%. The firm’s revenue was up 28.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.53) EPS. As a group, sell-side analysts predict that Inspire Medical Systems, Inc. will post 0.16 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently commented on INSP. Mizuho reissued a “buy” rating and set a $250.00 price target on shares of Inspire Medical Systems in a research note on Wednesday, March 27th. Piper Sandler increased their price objective on shares of Inspire Medical Systems from $250.00 to $255.00 and gave the company an “overweight” rating in a research note on Wednesday, May 8th. Truist Financial reiterated a “buy” rating and issued a $280.00 price target on shares of Inspire Medical Systems in a research report on Wednesday, March 20th. Royal Bank of Canada started coverage on Inspire Medical Systems in a report on Friday, April 19th. They set an “outperform” rating and a $285.00 target price on the stock. Finally, Morgan Stanley initiated coverage on Inspire Medical Systems in a report on Tuesday, March 19th. They issued an “overweight” rating and a $250.00 price target for the company. Five investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $253.87.

Check Out Our Latest Report on Inspire Medical Systems

Insider Buying and Selling

In other news, Director Jerry C. Griffin sold 554 shares of the company’s stock in a transaction dated Monday, March 18th. The shares were sold at an average price of $193.53, for a total value of $107,215.62. Following the sale, the director now owns 10,190 shares in the company, valued at approximately $1,972,070.70. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Inspire Medical Systems news, CEO Timothy P. Herbert sold 40,000 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $205.09, for a total transaction of $8,203,600.00. Following the completion of the sale, the chief executive officer now owns 63,658 shares in the company, valued at $13,055,619.22. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Jerry C. Griffin sold 554 shares of the stock in a transaction on Monday, March 18th. The stock was sold at an average price of $193.53, for a total transaction of $107,215.62. Following the sale, the director now directly owns 10,190 shares in the company, valued at $1,972,070.70. The disclosure for this sale can be found here. Over the last quarter, insiders sold 60,527 shares of company stock worth $12,730,533. Insiders own 4.10% of the company’s stock.

About Inspire Medical Systems

(Free Report)

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.

Featured Articles

Want to see what other hedge funds are holding INSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inspire Medical Systems, Inc. (NYSE:INSPFree Report).

Institutional Ownership by Quarter for Inspire Medical Systems (NYSE:INSP)

Receive News & Ratings for Inspire Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inspire Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.